A Function Variant at miR-501 Alters Susceptibility to Hepatocellular Carcinoma in a Chinese Han Population

Cellular Physiology and Biochemistry

Volumn 38, Issue 6, 2016, Pages 2500-2508

  Liu, Yang ^a   Chai, Yi ^b   Zhang, Jian ^a   Tang, Junwei ^b  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CYLD; HCC; miR 501; Polymorphism; Proliferation

Indexed keywords

MICRORNA; MICRORNA 501; UNCLASSIFIED DRUG; MIRN501 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ALLELE; APOPTOSIS; ARTICLE; BIOINFORMATICS; CARCINOGENESIS; CASE CONTROL STUDY; CELL PROLIFERATION; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; CYLD GENE; FEMALE; FLOW CYTOMETRY; GENE; GENE CONTROL; GENE FUNCTION; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CHINA; GENETIC PREDISPOSITION; GENETICS; LIVER; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84975783292     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000445600     Document Type: Article

References (35)

1. Trepo C, Chan HL, Lok A: Hepatitis B virus infection. Lancet 2014;384:2053-2063.
2. Jiang DK, Sun J, Cao G, Liu Y, Lin D, Gao YZ, Ren WH, Long XD, Zhang H, Ma XP, Wang Z, Jiang W, Chen TY, Gao Y, Sun LD, Long JR, Huang HX, Wang D, Yu H, Zhang P, Tang LS, Peng B, Cai H, Liu TT, Zhou P, Liu F, Lin X, Tao S, Wan B, Sai-Yin HX, Qin LX, Yin J, Liu L, Wu C, Pei Y, Zhou YF, Zhai Y, Lu PX, Tan A, Zuo XB, Fan J, Chang J, Gu X, Wang NJ, Li Y, Liu YK, Zhai K, Zhang H, Hu Z, Liu J, Yi Q, Xiang Y, Shi R, Ding Q, Zheng W, Shu XO, Mo Z, Shugart YY, Zhang XJ, Zhou G, Shen H, Zheng SL, Xu J, Yu L: Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet 2013;45:72-75.
3. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, Ravikumar S, Srivastava S, Tian X, Poon RT, Fan ST, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG: Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 2013;368:2266-2276.
4. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM: Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 2015;149:1226-1239 e1224.
5. Arzumanyan A, Reis HM, Feitelson MA: Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013;13:123-135.
6. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-687.
7. Levi AD, Wallace MC, Bernstein M, Walters BC: Venous thromboembolism after brain tumor surgery: a retrospective review. Neurosurgery 1991;28:859-863.
8. Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, Ikeda K, Kumada H, Toyota J, Morizono T, Tsunoda T, Kubo M, Nakamura Y, Kamatani N, Chayama K: Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 2011;43:797-800.
9. GoDarts, Group UDPS, Wellcome Trust Case Control C, Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, Burch L, Carr F, Strange A, Freeman C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Gray E, Hunt S, Jankowski J, Langford C, Markus HS, Mathew CG, Plomin R, Rautanen A, Sawcer SJ, Samani NJ, Trembath R, Viswanathan AC, Wood NW, investigators M, Harries LW, Hattersley AT, Doney AS, Colhoun H, Morris AD, Sutherland C, Hardie DG, Peltonen L, McCarthy MI, Holman RR, Palmer CN, Donnelly P, Pearson ER: Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;43:117-120.
10. Ling H, Fabbri M, Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-865.
11. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao W, Cao X: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011;19:232-243.
12. Chang Y, Yan W, He X, Zhang L, Li C, Huang H, Nace G, Geller DA, Lin J, Tsung A: miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology 2012;143:177-187 e178.
13. Tang J, Zhuo H, Zhang X, Jiang R, Ji J, Deng L, Qian X, Zhang F, Sun B: A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. Cell Death Dis 2014;5:e1549.
14. Tang W, Tang J, He J, Zhou Z, Qin Y, Qin J, Li B, Xu X, Geng Q, Jiang W, Wu W, Wang X, Xia Y: SLIT2/ROBO1-miR-218-1-RET/PLAG1: a new disease pathway involved in Hirschsprung's disease. J Cell Mol Med 2015;19:1197-1207.
15. Gao F, Sun X, Wang L, Tang S, Yan C: Downregulation of MicroRNA-145 Caused by Hepatitis B Virus X Protein Promotes Expression of CUL5 and Contributes to Pathogenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cell Physiol Biochem 2015;37:1547-1559.
16. Hu X, Zhang F, Liu XR, Wu YT, Ni YM: Efficacy and potential microRNA mechanism for computed tomography-guided percutaneous radiofrequency ablation of primary lung cancer and lung metastasis from liver cancer. Cell Physiol Biochem 2014;33:1261-1271.
17. Zheng M, Sun X, Li Y, Zuo W: MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1. Tumour Biol 2015;10.1007/s13277-015-4722-2
18. Sun Q, Gu H, Zeng Y, Xia Y, Wang Y, Jing Y, Yang L, Wang B: Hsa-miR-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression. Cancer Sci 2010;101:2241-2247.
19. Wang R, Zhang J, Ma Y, Chen L, Guo S, Zhang X, Ma Y, Wu L, Pei X, Liu S, Wang J, Hu H, Liu J: Association study of miR149 rs2292832 and miR608 rs4919510 and the risk of hepatocellular carcinoma in a largescale population. Mol Med Rep 2014;10:2736-2744.
20. Huang DH, Wang GY, Zhang JW, Li Y, Zeng XC, Jiang N: MiR-501-5p regulates CYLD expression and promotes cell proliferation in human hepatocellular carcinoma. Jpn J Clin Oncol 2015;45:738-744.
21. Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, Sun J, Guo AY: Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat 2012;33:254-263.
22. Wang Y, Wu P, Lin R, Rong L, Xue Y, Fang Y: LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia. Sci Rep 2015;5:13749.
23. Ishikawa Y, Tsunoda K, Shibazaki M, Takahashi K, Akasaka T, Masuda T, Maesawa C: Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity. Int J Oncol 2012;41:53-60.
24. Shiver M, Hughes M, Naylor M, McLarney B, Stolle C, Shalin S, Gao L: A novel CYLD gene mutation and multiple basal cell carcinomas in a patient with Brooke-Spiegler syndrome. Clin Exp Dermatol 2016;41:98-100.
25. Degagne E, Pandurangan A, Bandhuvula P, Kumar A, Eltanawy A, Zhang M, Yoshinaga Y, Nefedov M, de Jong PJ, Fong LG, Young SG, Bittman R, Ahmedi Y, Saba JD: Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. J Clin Invest 2014;124:5368-5384.
26. Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C, Massoumi R: CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis 2014;35:461-468.
27. Gringhuis SI, Kaptein TM, Wevers BA, Mesman AW, Geijtenbeek TB: Fucose-specific DC-SIGN signalling directs T helper cell type-2 responses via IKKepsilon-and CYLD-dependent Bcl3 activation. Nat Commun 2014;5:3898.
28. Ke H, Augustine CK, Gandham VD, Jin JY, Tyler DS, Akiyama SK, Hall RP, Zhang JY: CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and beta1-integrin signaling pathways. J Invest Dermatol 2013;133:221-229.
29. Gautheron J, Luedde T: A novel player in inflammation and cancer: the deubiquitinase CYLD controls HCC development. J Hepatol 2012;57:937-939.
30. Urbanik T, Kohler BC, Boger RJ, Worns MA, Heeger S, Otto G, Hovelmeyer N, Galle PR, Schuchmann M, Waisman A, Schulze-Bergkamen H: Down-regulation of CYLD as a trigger for NF-kappaB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol 2011;38:121-131.
31. Zhao H, Xu J, Zhao D, Geng M, Ge H, Fu L, Zhu Z: Somatic Mutation of the SNP rs11614913 and Its Association with Increased MIR 196A2 Expression in Breast Cancer. DNA Cell Biol 2015;10.1089/ dna.2014.2785
32. Dai ZJ, Shao YP, Wang XJ, Xu D, Kang HF, Ren HT, Min WL, Lin S, Wang M, Song ZJ: Five common functional polymorphisms in microRNAs (rs2910164, rs2292832, rs11614913, rs3746444, rs895819) and the susceptibility to breast cancer: evidence from 8361 cancer cases and 8504 controls. Curr Pharm Des 2015;21:1455-1463.
33. Liu CJ, Tsai MM, Tu HF, Lui MT, Cheng HW, Lin SC: miR-196a overexpression and miR-196a2 gene polymorphism are prognostic predictors of oral carcinomas. Ann Surg Oncol 2013;20 Suppl 3:S406-414.
34. Zhou J, Zhou J, Wang W, Li W, Wu L, Li G, Shi J, Zhou S: The polymorphism in miR-25 attenuated the oncogenic function in gastric cancer. Tumour Biol 2015;10.1007/s13277-015-4376-0
35. Liu C, Zhang Y, Chen H, Jiang L, Xiao D: Function analysis of rs9589207 polymorphism in miR-92a in gastric cancer. Tumour Biol 2015;10.1007/s13277-015-4288-z.